Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs StackMD

Coivas
Graded #198

Higher grade

vs+2.8000000000000043
StackMD
Graded #259

Lower grade

The verdict

Coivas takes it — 66.2/100 to 63.4/100.

Coivas grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Coivas is an all-inclusive GLP-1 telehealth service operated by WellVi LLC (d/b/a Coivas) with prescriptions through Arora Health & Aesthetics, LLC.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoivas +24
70
46
Dose & formulationCoivas +10
64
54
Clinical oversightCoivas +6
84
78
Labs & monitoringStackMD +8
54
62
FulfillmentStackMD +11
78
89
Contract termsStackMD +49
20
69
Coivas · left barStackMD · right bar

The numbers

MetricCoivasStackMD
WeighScore66.2/10063.4/100
GradeCC
Scorecard rank#198#259
Semaglutide$149/mo (quarterly plan, compounded)$125/mo (1 mg dose, plus a separate fee, compounded)
Tirzepatide$229/mo (quarterly plan, compounded)$199/mo (5 mg dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Coivas

Graded #198 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
StackMD

Graded #259 · C

Strengths

  • Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
  • Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
  • No membership or platform fee — the medication price is the whole price
  • States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility

Where it loses points

  • All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
  • Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
  • Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
  • Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
  • Terms impose binding arbitration in New York and waive jury trial and class-action participation

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard